Dasatinib Terminated Phase 2 Trials for Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01488318Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma